loading...| Preferred Name |
Indomethacin |
|
| Synonyms |
|
|
| Definitions |
A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C576 |
|
| Accepted_Therapeutic_Use_For |
Dysmennorhea; Inflammatory disorders; Pain |
|
| ALT_DEFINITION |
A drug that reduces pain, fever, swelling, and redness. It is also being used to reduce tumor-induced suppression of the immune system and to increase the effectiveness of anticancer drugs. It is a type of nonsteroidal anti-inflammatory drug (NSAID). |
|
| CAS_Registry |
53-86-1 |
|
| CHEBI_ID |
CHEBI:49662 |
|
| Chemical_Formula |
C19H16ClNO4 |
|
| code |
C576 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04) |
|
| Display_Name |
Indomethacin |
|
| FDA_UNII_Code |
XXE1CET956 |
|
| Has_Salt_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Indomethacin |
|
| Legacy Concept Name |
Indomethacin |
|
| Maps_To |
Indomethacin |
|
| NCI_Drug_Dictionary_ID |
39489 |
|
| NSC Number |
77541 |
|
| PDQ_Closed_Trial_Search_ID |
39489 |
|
| PDQ_Open_Trial_Search_ID |
39489 |
|
| Preferred_Name |
Indomethacin |
|
| prefixIRI |
NCIT:C576 |
|
| prefLabel |
Indomethacin |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0021246 |
|
| subClassOf |